X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (107534) 107534
Book Review (15535) 15535
Publication (5949) 5949
Book / eBook (183) 183
Conference Proceeding (179) 179
Newsletter (95) 95
Book Chapter (75) 75
Magazine Article (45) 45
Dissertation (34) 34
Newspaper Article (33) 33
Transcript (28) 28
Paper (5) 5
Data Set (3) 3
Presentation (3) 3
Reference (3) 3
Report (2) 2
Trade Publication Article (2) 2
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (103058) 103058
index medicus (102192) 102192
antineoplastic combined chemotherapy protocols - therapeutic use (70844) 70844
female (68431) 68431
male (56190) 56190
middle aged (54285) 54285
oncology (53461) 53461
aged (45380) 45380
adult (43932) 43932
chemotherapy (33053) 33053
treatment outcome (26600) 26600
cancer (26223) 26223
antineoplastic combined chemotherapy protocols - adverse effects (24446) 24446
antineoplastic combined chemotherapy protocols - administration & dosage (21163) 21163
cisplatin - administration & dosage (20049) 20049
combined modality therapy (18046) 18046
fluorouracil - administration & dosage (15700) 15700
doxorubicin - administration & dosage (14582) 14582
cyclophosphamide - administration & dosage (14129) 14129
neoplasm staging (13778) 13778
prognosis (13634) 13634
drug administration schedule (12979) 12979
aged, 80 and over (12536) 12536
disease-free survival (12178) 12178
animals (12147) 12147
survival rate (11973) 11973
hematology (11765) 11765
therapy (11622) 11622
care and treatment (11534) 11534
breast neoplasms - drug therapy (10904) 10904
adolescent (10465) 10465
retrospective studies (10155) 10155
lung neoplasms - drug therapy (10147) 10147
vincristine - administration & dosage (10063) 10063
survival analysis (10046) 10046
cisplatin (9928) 9928
antineoplastic agents - therapeutic use (9717) 9717
follow-up studies (9051) 9051
medicine & public health (8823) 8823
survival (8739) 8739
antineoplastic agents - administration & dosage (8541) 8541
chemotherapy, adjuvant (8329) 8329
etoposide - administration & dosage (8085) 8085
remission induction (8045) 8045
pharmacology & pharmacy (7933) 7933
carcinoma (7729) 7729
mice (7581) 7581
abridged index medicus (7580) 7580
paclitaxel - administration & dosage (7550) 7550
research (7501) 7501
deoxycytidine - analogs & derivatives (7373) 7373
trial (7352) 7352
dose-response relationship, drug (7294) 7294
radiotherapy (6978) 6978
surgery (6773) 6773
analysis (6632) 6632
cell line, tumor (6536) 6536
deoxycytidine - administration & dosage (6527) 6527
carboplatin - administration & dosage (6518) 6518
antineoplastic agents (6460) 6460
methotrexate - administration & dosage (6438) 6438
tumors (6412) 6412
breast cancer (6389) 6389
child (6379) 6379
hematology, oncology and palliative medicine (6101) 6101
time factors (6087) 6087
prospective studies (6067) 6067
carcinoma, non-small-cell lung - drug therapy (6027) 6027
breast neoplasms - pathology (5947) 5947
adenocarcinoma - drug therapy (5893) 5893
antimitotic agents (5779) 5779
drug therapy (5756) 5756
prednisone - administration & dosage (5742) 5742
health aspects (5598) 5598
neoplasm metastasis (5544) 5544
metastasis (5464) 5464
paclitaxel (5426) 5426
leucovorin - administration & dosage (5059) 5059
clinical trials as topic (5022) 5022
combination (5015) 5015
antineoplastic combined chemotherapy protocols - pharmacology (5010) 5010
neoplasms - drug therapy (4974) 4974
apoptosis (4812) 4812
fluorouracil (4806) 4806
clinical trials (4757) 4757
antineoplastic agents - adverse effects (4729) 4729
young adult (4716) 4716
cytarabine - administration & dosage (4686) 4686
colorectal neoplasms - drug therapy (4664) 4664
doxorubicin (4646) 4646
cyclophosphamide (4630) 4630
child, preschool (4575) 4575
taxoids - administration & dosage (4533) 4533
risk factors (4532) 4532
phase-ii (4523) 4523
ovarian neoplasms - drug therapy (4470) 4470
lung neoplasms - pathology (4446) 4446
organoplatinum compounds - administration & dosage (4390) 4390
vinblastine - administration & dosage (4261) 4261
toxicity (4198) 4198
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (141) 141
Collection Dvlpm't (Acquisitions) - Vendor file (10) 10
Collection Dvlpm't (Acquisitions) - Closed Orders (8) 8
Online Resources - Online (4) 4
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (4) 4
Chemistry (A D Allen) - Stacks (2) 2
Gerstein Science - Circulation Desk (2) 2
Credit Valley Hospital - Stacks (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Sunnybrook Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Oshawa (1) 1
UTL at Downsview - May be requested (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (94688) 94688
Japanese (7243) 7243
German (1235) 1235
Chinese (1225) 1225
French (1200) 1200
Russian (738) 738
Spanish (499) 499
Polish (310) 310
Italian (289) 289
Hungarian (147) 147
Czech (72) 72
Dutch (56) 56
Hebrew (32) 32
Bulgarian (27) 27
Ukrainian (27) 27
Danish (25) 25
Portuguese (21) 21
Serbian (19) 19
Romanian (17) 17
Korean (16) 16
Norwegian (15) 15
Croatian (13) 13
Finnish (11) 11
Swedish (9) 9
Slovak (6) 6
Lithuanian (5) 5
Turkish (3) 3
Afrikaans (1) 1
Arabic (1) 1
Bosnian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 375 - 384
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9742, pp. 687 - 697
Summary Background Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | SUPPORTIVE CARE | MEDICINE, GENERAL & INTERNAL | METASTATIC BREAST-CANCER | ADVANCED ESOPHAGOGASTRIC CANCER | GENE AMPLIFICATION | 1ST-LINE THERAPY | HER2 | FLUOROURACIL | III TRIAL | PLUS | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Capecitabine | Humans | Middle Aged | Stomach Neoplasms - metabolism | Male | Antineoplastic Agents - administration & dosage | Cisplatin - administration & dosage | Antibodies, Monoclonal, Humanized | Adenocarcinoma - metabolism | Fluorouracil - administration & dosage | Female | Drug Therapy, Combination | Receptor, ErbB-2 - biosynthesis | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Esophagogastric Junction | Antibodies, Monoclonal - administration & dosage | Survival Analysis | Aged | Stomach Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Trastuzumab | Adenocarcinoma - mortality | Chemotherapy | Gastrointestinal cancer | Patient outcomes | Drug therapy, Combination | Drug therapy | Methods | Cancer | Voice recognition | Heart failure | Clinics | Heart attacks | Breast cancer | Blood pressure | Clinical medicine | Angina pectoris | Cancer therapies | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2013, Volume 31, Issue 7, pp. 860 - 867
Journal Article
Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
TRIAL | SURVIVAL | PLUS DEXAMETHASONE | COMPLETE REMISSION | HIGH-DOSE THERAPY | COMPLETE RESPONSE | DOXORUBICIN | PERIPHERAL NEUROPATHY | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Summary Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of... 
Internal Medicine | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | II MULTICENTER | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | CYCLOPHOSPHAMIDE | VINCRISTINE | NON-HODGKINS-LYMPHOMA | COMBINATION | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology | Index Medicus | Abridged Index Medicus
Journal Article